ImmunityBio, Inc. (IBRX) saw its stock price soar 5.28% during Tuesday's trading session, reflecting strong positive momentum for the biopharmaceutical company.
The significant upward movement was primarily driven by positive analyst sentiment, specifically the reaffirmation of a Buy rating on ImmunityBio by HC Wainwright & Co. Such analyst actions frequently influence investor perception and can catalyze stock price movements, especially when a reputable firm maintains a bullish stance on a company's prospects.